BridgeMD
New treatment option for Cancer
Official title Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
ClinicalTrials.gov ID: NCT03787056
What this study is testing
- What it's testing
- Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric acids during digestion.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically and/or cytologically documented (documentation obtained before or after diagnostic surgical procedure when clinical suspicion is...
- Head and neck carcinomas
- Thyroid cancer
- Pancreatic carcinomas
- Ovarian adenocarcinomas
See the full eligibility criteria
Who can join
- Histologically and/or cytologically documented (documentation obtained before or after diagnostic surgical procedure when clinical suspicion is strong), cancers for the following cohorts: o Breast carcinomas o Gastric...
- Head and neck carcinomas
- Thyroid cancer
- Pancreatic carcinomas
- Ovarian adenocarcinomas
- Glioblastoma
- Endometrial adenocarcinomas
- Bladder carcinoma
- Superficial Oesophago-gastric carcinomas
- Diffuse Large B-cell Lymphomas
- Patient older than 18 years.
- Patients who gave its written informed consent to participate to the study
- Patients affiliated to a social insurance regime Specific for curative treatment strategy cancer patients:
- Indication of a treatment strategy with curative intent (surgery; radiotherapy; chemotherapy; hormonotherapy; targeted agents…)
- Patient naïve of anticancer treatments for the considered cancer
- A prior anti-cancer treatment is allowed if this treatment was performed with curative intent, and if it did not include systemic chemotherapy, and if a complete remission ≥ 6 months was observed in between the end of...
- Indication of a treatment strategy with no curative intent (radiotherapy; chemotherapy; hormonotherapy; immunotherapy; targeted agents, non-curative surgery, …)
- Patient naïve of anticancer treatments in non-curative setting (except for metastatic hormone-sensitive prostate cancer, see specific ). The following tumor type specific must be met in addition to the listed above...
- All cohorts:
- Invasive breast ductal carcinoma, or
- Invasive breast lobular carcinoma
- Curative intent treatment patient cohort:
- Planned to be treated with surgery, with/without neo-adjuvant and/or adjuvant chemotherapy and/or anti-hormone treatment Gastric carcinomas
- All cohorts: o Intestinal-type adenocarcinoma, or o Diffuse cell type adenocarcinoma
- Curative intent treatment patient cohort:
- Planned to be treated with surgery with/without neo-adjuvant treatment, with/without adjuvant treatment Renal carcinomas All cohorts:
- Any histology of renal cancer is accepted (non-clear cell renal cancer could be included)
- A pathology proof of renal cell carcinoma is not necessarily provided if patients present typical radiologic characteristics of renal cancer on imaging
- Curative intent treatment patients cohort:
- Planned to be treated with partial or total nephrectomy Prostate carcinomas
- Curative intent treatment patients cohort: o Localized prostate cancer with high risk features : StageT2b , T2c or T3 and/or Gleason \>= 4+3 and/or PSA \>= 20 and/or N+ o Planned to be treated with radical prostatectomy...
- Non-curative intent treatment patients cohort:
- Patients with metastatic castration resistant prostate cancer (mCRPC) defined by validated criteria of EAU, planned to be treated with doceteaxel or cabazitaxel or second generation hormone (i.e. abiraterone or...
- Non-curative intent patients cohort: o NSCLC stage IV according to 8th TNM classification planned to be treated with immunotherapy, with/ without chemotherapy Lung carcinomas excluding those treated with immunotherapy:
- Curative intent treatment patients cohort: o NSCLC histology only o Stage I-II according to 8th TNM classification o Stage IIIA-B according to 8th TNM classification o Planned to be treated with radical treatment...
- Non-curative intent patients cohort:
- NSCLC or SCLC stage IV according to 8th TNM classification planned to be treated with a first line of chemotherapy, with/without associated treatments except immunotherapy (radiotherapy, targeted therapies…)...
- Absence or chronic hepatic encephalopathy, absence of refractory ascites
- Curative intent treatment patients cohort:
- Indication of a treatment strategy with curative intent, except liver transplantation: surgical resection, monopolar radiofrequency ablation for HCC (1 to 3 nodules ≤3 cm) or multibipolar radiofrequency if nodule ≤4 cm).
- Non-curative intent patients cohort:
- Indication of a treatment strategy with no curative intent: transarterial intra-hepatic chemoembolization, targeted therapies (tyrosine kinase inhibitors or monoclonal antibodies) or immune therapy. Colorectal carcinomas
- Curative intent treatment patients cohort: o Lieberkühn adenocarcinoma associated with metastases planned to be treated with peri-operative chemotherapy +/- targeted agent and interval surgery Head and neck carcinomas
- All cohorts o Head and neck squamous cell carcinoma from oral cavity, oropharynx, hypopharynx, larynx
- Curative intent treatment patients cohort: o Planned to be treated with a radical treatment (surgery and/or radiotherapy potentially associated with concurrent chemotherapy) with/without neo-adjuvant/adjuvant...
- Non-curative intent treatment patients cohort: o De novo metastatic or metastatic/loco-regional relapse planned to be treated with chemotherapy and/or immunotherapy Thyroid cancer Curative intent patient cohort o...
- Curative intent patients cohort: o Pancreas exocrine adenocarcinoma planned to be treated with initial surgery with/without neo-adjuvant chemotherapy and with/without adjuvant chemotherapy or radiotherapy Ovarian...
- High or low grade epithelial adenocarcinomas or carcinosarcoma
- Planned to be treated with chemotherapy and/or PARP inhibitors based treatment, +/- interval debulking surgery Glioblastoma Curative intent patients cohort: o Planned to be treated with surgical resection, followed by...
- Non-curative intent patients cohort: o Type 1 (endometrioid or mucinous) or type 2 endometrial (serous, clear cell, undifferentiated carcinoma and carcinosarcoma) cancers o Planned to be treated with non-curative...
- Transitional cell carcinoma Curative intent treatment patients:
- Patients with localized muscle invasive bladder cancer (\>=PT2)
- Planned to be treated with neo-adjuvant cisplatin based chemotherapy, or immunotherapy or a combination of chemotherapy and immunotherapy Superficial Oesophago-gastric cancer Curative intent patients cohort: o...
- Curative intent patients cohort: o Patients planned to be treated with R-CHOP (Rituximab-Cyclophosphamide, Hydroxyadriamycine, Oncovin, Prednisone)
The study team makes the final eligibility decision.
Where it's taking place
- Bron, France
- Lyon, France
- Pierre-Bénite, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bron, France; Lyon, France; Pierre-Bénite, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.